July 27, 2016 8:20 PM ET

Biotechnology

Company Overview of Intercell USA, Inc.

Company Overview

Intercell USA, Inc. is a biopharmaceutical company that focuses on furthering the science and product application of transcutaneous immunization (TCI) in the prevention and treatment of infectious and autoimmune diseases, cancer, and allergies. The company focuses on the delivery of vaccines and immunostimulants to the skin through transcutaneous immunization technology. Intercell USA, Inc. was formerly known as Iomai Corporation and changed its name to Intercell USA, Inc. in August 2008 as a result of its acquisition by Intercell Ag. The company was founded in 1997 and is based in Gaithersburg, Maryland. As of August 5, 2008, Intercell USA, Inc. operates as a subsidiary of Valneva SE.

20 Firstfield Road

Suite 250

Gaithersburg, MD 20878

United States

Founded in 1997

110 Employees

Phone:

301-556-4500

Fax:

301-556-4501

Key Executives for Intercell USA, Inc.

Chief Executive Officer and Director
Age: 61
President and Director
Age: 53
Chief Financial Officer and Secretary
Age: 47
Vice President of Operations
Age: 48
Vice President of Human Resources
Compensation as of Fiscal Year 2016.

Intercell USA, Inc. Key Developments

Intercell USA Inc. Wins $32.49 Million Federal Contract to Supply of Japanese Encephalitis Vaccines

Intercell USA Inc. was awarded a sole source federal contract set aside for small business valued at up to $32,488,750 by the Defense Logistics Agency for the supply of the Japanese encephalitis vaccines to be used by the U.S. Air Force, U.S. Army, U.S. Marine Corps and U.S. Navy in Maryland.

Intercell USA, Inc. Announces U.S. Distribution and Marketing Services Agreements with VaxServe, Inc

Valneva SE announced that its fully owned US subsidiary Intercell USA, Inc. has entered into distribution and marketing services agreements with VaxServe, Inc. for Valneva's Japanese encephalitis (JE) vaccine IXIARO in the United States (U.S.). This collaboration is part of Valneva's strategy to commercialize IXIARO through a combination of its own sales & marketing infrastructure and distribution agreements with established local partners at favorable terms. Under the terms of the agreements, VaxServe will perform marketing and promotional services and distribute Valneva's Japanese encephalitis vaccine exclusively in the U.S. private market beginning December 18, 2015. Through the agreements, Valneva and VaxServe are working together to increase the private market for IXIARO vaccine in the U.S. he agreements do not include the distribution of the vaccine by VaxServe to the public market, including the U.S. military and other federal governmental agencies, which Valneva will handle directly.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Intercell USA, Inc., please visit www.iomai.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.